Previous 10 | Next 10 |
home / stock / azncf / azncf news
2024-01-28 20:15:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund® (the Fund) gained 7.78% (Institutional Shares) d...
2024-01-22 10:08:03 ET Summary While UK stocks are currently valued lower than their U.S. counterparts, a closer examination reveals concerns such as stagnant financial and energy companies with limited growth potential. In contrast, UK small and mid-cap companies show more promis...
2024-01-22 08:50:51 ET Summary Positive preliminary results were achieved in early-stage studies of its protein degraders, NX-2127 and NX-5948, for the treatment of B-cell malignancies. Protein degradation platform offers several advantages over other BTK drugs, such as ability to...
2024-01-21 01:55:00 ET Summary Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in its ...
2024-01-09 18:04:24 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-01-07 07:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market bounced in ...
2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...
2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...
2023-12-27 16:11:16 ET Summary Gracell Biotechnologies has seen a 360% increase in its stock price YTD, with a particular boost since AstraZeneca decided to acquire it for USD $1.2 billion. The acquisition price sounds fair, and the run-up following the announcement leaves little ...
2023-12-26 03:42:42 ET More on AstraZeneca, Gracell Biotechnologies: AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Pays Hefty Price For Chinese Weight-Loss Drug FDA approves AstraZeneca, Ionis drug for ATTRv-PN Gracell gain...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...